{"id":68196,"date":"2026-06-15T20:56:46","date_gmt":"2026-06-15T12:56:46","guid":{"rendered":"https:\/\/flcube.com\/?p=68196"},"modified":"2026-06-15T20:56:47","modified_gmt":"2026-06-15T12:56:47","slug":"astrazenecas-truqap-receives-fda-approval-as-first-targeted-therapy-for-pten-deficient-prostate-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68196","title":{"rendered":"AstraZeneca&#8217;s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>AstraZeneca plc (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NYSE: AZN<\/a>)<\/strong> announced that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved <strong>Truqap (capivasertib)<\/strong> in combination with <strong>abiraterone and prednisone<\/strong> for the treatment of adult patients with <strong>PTEN-deficient, metastatic, androgen-naive or androgen-sensitive prostate cancer (mAPMN\/S)<\/strong>, previously referred to as <strong>metastatic hormone-sensitive prostate cancer (mHSPC)<\/strong>. This marks the <strong>first and only targeted treatment option<\/strong> for this specific biomarker-defined prostate cancer population.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (United States)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Full approval<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Truqap (capivasertib) + abiraterone + prednisone<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>PTEN-deficient mAPMN\/S (formerly mHSPC)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Adult patients with PTEN-deficient metastatic prostate cancer<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First targeted therapy for this indication<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Capivasertib \u2013 first-in-class, potent ATP-competitive inhibitor of AKT isoforms (AKT1\/2\/3)<\/li>\n\n\n\n<li><strong>Target Pathway:<\/strong> PI3K\/AKT\/PTEN signaling pathway<\/li>\n\n\n\n<li><strong>Biomarker Requirement:<\/strong> PTEN deficiency as predictive biomarker for treatment selection<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong> Synergistic approach combining AKT inhibition with androgen receptor pathway blockade<\/li>\n\n\n\n<li><strong>Therapeutic Innovation:<\/strong> Represents precision medicine approach in prostate cancer treatment<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-previous-approvals-amp-development-history\" class=\"wp-block-heading\">Previous Approvals &amp; Development History<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Indication<\/th><th>Approval Status<\/th><th>Combination Partner<\/th><th>Biomarker Requirements<\/th><\/tr><\/thead><tbody><tr><td><strong>HR+\/HER2- Breast Cancer<\/strong><\/td><td>Previously approved in US<\/td><td>Faslodex (fulvestrant)<\/td><td>PIK3CA, AKT1, or PTEN alterations<\/td><\/tr><tr><td><strong>PTEN-deficient Prostate Cancer<\/strong><\/td><td>Newly approved<\/td><td>Abiraterone + prednisone<\/td><td>PTEN deficiency<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-breast-cancer-approval-details\" class=\"wp-block-heading\">Breast Cancer Approval Details<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Population:<\/strong> HR-positive (ER-positive), HER2-negative locally advanced or metastatic breast cancer<\/li>\n\n\n\n<li><strong>Patient Criteria:<\/strong> Relapsed or progressed on endocrine-based regimen<\/li>\n\n\n\n<li><strong>Biomarkers:<\/strong> PIK3CA, AKT1, or PTEN alterations<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-competitive-positioning\" class=\"wp-block-heading\">Market Impact &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prostate Cancer Landscape:<\/strong> Addresses significant unmet need in biomarker-defined subset of mHSPC patients<\/li>\n\n\n\n<li><strong>Precision Medicine Advance:<\/strong> First targeted therapy specifically for PTEN-deficient prostate cancer<\/li>\n\n\n\n<li><strong>Commercial Opportunity:<\/strong> Expands Truqap&#8217;s addressable market beyond breast cancer into prostate cancer<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> No other targeted therapies currently approved for PTEN-deficient mHSPC<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This approval represents a major milestone in <strong>precision oncology for prostate cancer<\/strong>, leveraging AstraZeneca&#8217;s expertise in <strong>targeted therapies<\/strong> and <strong>biomarker-driven development<\/strong>. The success of capivasertib in both breast and prostate cancers demonstrates the <strong>broad applicability of AKT pathway inhibition<\/strong> across tumor types with PI3K\/AKT\/PTEN pathway alterations.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-context\" class=\"wp-block-heading\">Clinical Development Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Trial Design:<\/strong> Likely based on biomarker-selected Phase III trial demonstrating superiority over standard of care<\/li>\n\n\n\n<li><strong>Endpoint Achievement:<\/strong> Significant improvement in progression-free survival and\/or overall survival<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Manageable toxicity profile consistent with AKT inhibition mechanism<\/li>\n\n\n\n<li><strong>Biomarker Testing:<\/strong> Companion diagnostic development likely required for patient selection<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-next-steps-amp-future-outlook\" class=\"wp-block-heading\">Next Steps &amp; Future Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Regulatory Submissions:<\/strong> Expected filings with EMA and other international agencies<\/li>\n\n\n\n<li><strong>Commercial Launch:<\/strong> Immediate availability through AstraZeneca&#8217;s established oncology distribution network<\/li>\n\n\n\n<li><strong>Additional Indications:<\/strong> Potential exploration in other PTEN-altered malignancies<\/li>\n\n\n\n<li><strong>Combination Strategies:<\/strong> Further development with novel agents in prostate cancer setting<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ due to risks including competitive dynamics, market adoption, and future clinical trial outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68197,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[130,4621],"class_list":["post-68196","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-astrazeneca","tag-nyse-azn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca&#039;s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with abiraterone and prednisone for the treatment of adult patients with PTEN-deficient, metastatic, androgen-naive or androgen-sensitive prostate cancer (mAPMN\/S), previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC). This marks the first and only targeted treatment option for this specific biomarker-defined prostate cancer population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68196\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca&#039;s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with abiraterone and prednisone for the treatment of adult patients with PTEN-deficient, metastatic, androgen-naive or androgen-sensitive prostate cancer (mAPMN\/S), previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC). This marks the first and only targeted treatment option for this specific biomarker-defined prostate cancer population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68196\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T12:56:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T12:56:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1505.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68196#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68196\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca&#8217;s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer\",\"datePublished\":\"2026-06-15T12:56:46+00:00\",\"dateModified\":\"2026-06-15T12:56:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68196\"},\"wordCount\":479,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68196#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1505.webp\",\"keywords\":[\"AstraZeneca\",\"NYSE:\u202fAZN\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68196#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68196\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68196\",\"name\":\"AstraZeneca's Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68196#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68196#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1505.webp\",\"datePublished\":\"2026-06-15T12:56:46+00:00\",\"dateModified\":\"2026-06-15T12:56:47+00:00\",\"description\":\"AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with abiraterone and prednisone for the treatment of adult patients with PTEN-deficient, metastatic, androgen-naive or androgen-sensitive prostate cancer (mAPMN\\\/S), previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC). This marks the first and only targeted treatment option for this specific biomarker-defined prostate cancer population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68196#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68196\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68196#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1505.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1505.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca's Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68196#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca&#8217;s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca's Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with abiraterone and prednisone for the treatment of adult patients with PTEN-deficient, metastatic, androgen-naive or androgen-sensitive prostate cancer (mAPMN\/S), previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC). This marks the first and only targeted treatment option for this specific biomarker-defined prostate cancer population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68196","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca's Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer","og_description":"AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with abiraterone and prednisone for the treatment of adult patients with PTEN-deficient, metastatic, androgen-naive or androgen-sensitive prostate cancer (mAPMN\/S), previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC). This marks the first and only targeted treatment option for this specific biomarker-defined prostate cancer population.","og_url":"https:\/\/flcube.com\/?p=68196","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-15T12:56:46+00:00","article_modified_time":"2026-06-15T12:56:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1505.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68196#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68196"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca&#8217;s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer","datePublished":"2026-06-15T12:56:46+00:00","dateModified":"2026-06-15T12:56:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68196"},"wordCount":479,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68196#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1505.webp","keywords":["AstraZeneca","NYSE:\u202fAZN"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68196#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68196","url":"https:\/\/flcube.com\/?p=68196","name":"AstraZeneca's Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68196#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68196#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1505.webp","datePublished":"2026-06-15T12:56:46+00:00","dateModified":"2026-06-15T12:56:47+00:00","description":"AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with abiraterone and prednisone for the treatment of adult patients with PTEN-deficient, metastatic, androgen-naive or androgen-sensitive prostate cancer (mAPMN\/S), previously referred to as metastatic hormone-sensitive prostate cancer (mHSPC). This marks the first and only targeted treatment option for this specific biomarker-defined prostate cancer population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68196#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68196"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68196#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1505.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1505.webp","width":1080,"height":608,"caption":"AstraZeneca's Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68196#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca&#8217;s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1505.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68196"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68196\/revisions"}],"predecessor-version":[{"id":68198,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68196\/revisions\/68198"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68197"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}